Acusphere, Inc. 

(Public, OTC:ACUS)   Watch this stock   
Find more results for ACUS

Key stats and ratios

Q3 (Sep '08) 2007
Net profit margin -3033.33% -2014.62%
Operating margin -2930.97% -2019.98%
EBITD margin - -1636.11%
Return on average assets -146.88% -73.18%
Return on average equity - -136.31%
Employees 118 -

Address

500 Arsenal Street
Watertown, MA 02472
United States - Map
+1-617-6488800 (Phone)
+1-617-9263605 (Fax)

Website links

Acusphere, Inc. discussions

  View all discussions »

Description

Acusphere, Inc. is a specialty pharmaceutical company that develops drugs and formulations of existing drugs using its porous microparticle technology. This technology enables the Company to control the size and porosity of particles, including nanoparticles and microparticles, so that the particles can be customized to address the delivery needs of a variety of drugs. These product candidates include Imagify (perflubutane polymer microspheres for delivery in an injectable suspension, formerly known as AI-700), a cardiovascular drug for the detection of coronary artery disease; Hydrophobic Drug Delivery System (HDDS), which converts drugs that do not dissolve well in water into microparticles or nanoparticles of the drugs embedded in small microparticles; and Pulmonary Drug Delivery System (PDDS), which facilitates sustained release of asthma drugs by c

Officers and directors

Sherri C. Oberg
President, Chief Executive Officer, Director
Age: 48
Lawrence A. Gyenes
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 57
Michael R. Slater
Senior Vice President - Regulatory Affairs and Operations
Age: 60
Frank Baldino Jr., Ph.D.
Presiding Director
Age: 56
Martyn D. Greenacre
Director
Age: 67
Derek Lemke-von Ammon
Director
Age: 50
Sandra L. Fenwick
Director
Age: 57
Garen G. Bohlin
Director
Age: 60